Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy and TPP Insights

Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity resulting from the use of neurotoxic antineoplastic agents, most notably taxanes, platinum compounds, and vinca alkaloids. The pathogenesis involves multifaceted damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to the dorsal root ganglia, which are particularly vulnerable due to their high metabolic activity and permeable blood-nerve barrier. Clinically, CIPN manifests as a symmetric sensory impairment in a “glove-and-stocking” distribution, characterized by numbness, paresthesia, and burning pain, and may involve a “coasting” effect where symptoms progress even after treatment cessation. Risk is exacerbated by cumulative drug exposure, advanced age, and pre-existing conditions like diabetes. As there are currently no FDA-approved agents for the prevention of CIPN, management is primarily symptomatic—with the SNRI duloxetine serving as the first-line evidence-based intervention—while severe symptoms often necessitate clinical dose delays or permanent discontinuation of life-saving chemotherapy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)